Drugs / RNA CART-cMET
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 0 | NCT03060356 Comparator | Dec 2016 → Mar 2020 | breast cancer, melanoma | University of Pennsylvania | Terminated | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RNA CART-cMET | “referred to as "RNA CART-cMET"” NCT03060356 ↗ |
| Modality | Cell therapy | “cMET-directed CAR T-cell therapy” PMID 37377890 ↗ May 2023 |
| Route | Intravenous | “administered intravenously” NCT03060356 ↗ |
| Target | MET | “CAR T cells targeting the cell-surface antigen cMET” PMID 37377890 ↗ May 2023 |